Abivax Appoints Biopharma Veteran Dr. Dominik Höchli To Board Of Directors As Company Prepares For Ulcerative Colitis Phase 3 Results

Abivax SA has announced the immediate appointment of Dr. Dominik Höchli to its Board of Directors. Dr. Höchli brings extensive biopharma leadership experience, having held key global roles during his 20-year career at AbbVie and Abbott, including Vice President of Global Marketing for Immunology and Head of Global Medical Affairs.

Sylvie Grégoire, Chair of Abivax Board of Directors, commented, “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical strategy and commercialisation within immunology will be invaluable as we approach key clinical and regulatory inflexion points for obefazimod.”

 Dr. Höchli has a deep expertise in immunology and product strategy that will support Abivax as it moves toward a significant milestone, the Phase 3 data readout for its 8-week induction trial in ulcerative colitis, expected in the third quarter of 2025. His appointment strengthens the company’s leadership as it advances its therapeutics pipeline to regulate immune responses in chronic inflammatory conditions.

Dr. Dominik Höchli said,  “I’m excited to join the Board at a time when Abivax is entering a critical phase of clinical development and to support the company’s efforts to bring obefazimod to patients living with ulcerative colitis and Crohn’s disease.”

Including his experience at  AbbVie, Dr. Höchli previously served as interim CEO at Catapult Therapeutics and is the founder of the consulting firm Abinode. He also serves on the Board of Directors of Molecular Partners AG, contributing to both the Audit and R&D Committees.